Erica F. Clayton, Saloni Malik, Alexander Bonnel, Yifei Mu, Kim Olthoff, Abraham Shaked, Peter L. Abt, Heather Peterman, K. Rajender Reddy, Shane Ottmann, Emma E. Furth, Matthew H. Levine – 25 March 2014 – Liver transplantation has become the standard‐of‐care treatment for hepatocellular carcinoma (HCC) that falls within certain size and numerical criteria for patients with cirrhosis. Cirrhotomimetic (CMM) HCC is an uncommon growth pattern that infiltrates cirrhotic parenchyma, can become extensive in size, and can evade detection via radiological studies.

Irene Locatelli, Salvatore Sutti, Aastha Jindal, Marco Vacchiano, Cristina Bozzola, Chris Reutelingsperger, Dennis Kusters, Stefania Bena, Maurizio Parola, Claudia Paternostro, Elisabetta Bugianesi, Simon McArthur, Emanuele Albano, Mauro Perretti – 25 March 2014 – Annexin A1 (AnxA1) is an effector of the resolution of inflammation and is highly effective in terminating acute inflammatory responses. However, its role in chronic settings is less investigated.

Ricardo Marcos, Carla Correia‐Gomes – 25 March 2014

Jean‐François Dufour – 24 March 2014

Jean‐François Dufour – 24 March 2014

Sachin Batra, Victor I. Machicao, John S. Bynon, Shivang Mehta, Rajasekhar Tanikella, Michael J. Krowka, Steven Zacks, James Trotter, Kari E. Roberts, Robert S. Brown, Steven M. Kawut, Michael B. Fallon, for the Pulmonary Vascular Complications of Liver Disease Group – 22 March 2014 – Left ventricular hypertrophy (LVH) occurs in 12% to 30% of patients with cirrhosis; however, its prognostic significance is not well studied. We assessed the association of LVH with survival in patients undergoing a liver transplantation (LT) evaluation.

Moustafa Mabrouk Mourad, Christos Liossis, Bridget K. Gunson, Hynek Mergental, John Isaac, Paolo Muiesan, Darius F. Mirza, M. Thamara P. R. Perera, Simon R. Bramhall – 21 March 2014 – Hepatic artery thrombosis (HAT) represents a major cause of graft loss and mortality after liver transplantation. It occurs in up to 9% of adult recipients. The early diagnosis of HAT decreases septic complications, multiorgan failure, and graft loss, and there are better outcomes after treatment.

Tim O. Lankisch, Torsten Voigtländer, Michael P. Manns, Angelika Holzmann, Seema Dangwal, Thomas Thum – 20 March 2014 – Biliary complications after liver transplantation remain a major cause of morbidity and reduced graft survival. Ischemic‐type biliary lesions (ITBLs) are common and difficult to treat. The pathophysiology of ITBLs remains unclear, and diagnostic markers are still missing. The analysis of microRNA (miRNA) profiles is an evolving field in hepatology. Our aim was to identify specific miRNA patterns in the bile of patients with ITBLs after liver transplantation.

Saira Khaderi, Rashid Khan, Zeenath Safdar, Rise Stribling, John M. Vierling, John A. Goss, Norman L. Sussman – 20 March 2014 – Portopulmonary hypertension (POPH) occurs in 5.3% to 8.5% of patients with advanced liver disease. The rate of survival in the absence of orthotopic liver transplantation (OLT) is reportedly 38% at 3 years and 28% at 5 years. Moderate to severe POPH [mean pulmonary artery pressure (MPAP) ≥ 35 mm Hg] is associated with a perioperative mortality rate of 50%.

Ramadan M. Gharbawy, Bakr M. Nour – 20 March 2014